International Journal of Drug Delivery Technology
Volume 14, Issue 1

Antidiabetic Drug-loaded Solid Lipid Nanoparticle and Its Importance in Drug Delivery

Vijayakumar P1, Balaji P2*

1Department of Pharmaceutics, Vels Schools of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India.

2Department of Pharmaceutical Sciences, Vels Schools of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India. 

Received: 05th July, 2023; Revised: 31st January, 2024; Accepted: 29th February, 2024; Available Online: 25th March, 2024

ABSTRACT

The global health challenge of diabetes mellitus continues to escalate, affecting millions of people worldwide. Managing this chronic condition necessitates lifelong treatment to control hyperglycemia and prevent complications. The delivery of antidiabetic medications can be improved by solid lipid nanoparticles (SLNs). This review provides an overview of current research on antidiabetic-loaded SLNs, summarizing their efficacy, safety, and challenges. Various antidiabetic agents, including insulin, metformin, sulfonylureas, and GLP-1 agonists, have been successfully encapsulated into SLNs, offering improved pharmacokinetic profiles and therapeutic outcomes. Despite their potential, optimization of SLN formulations, scale-up challenges, and translation to clinical practice remain areas requiring further investigation. With ongoing advancements in nanotechnology and drug delivery, antidiabetic-loaded SLNs hold promise for revolutionizing diabetes therapy and improving patient care.

Keywords: Solid lipid nanoparticles, Antidiabetic, International Diabetes Federation, Insulin therapy, Nanocarrier. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.73

How to cite this article: Vijayakumar P, Balaji P. Antidiabetic Drug-loaded Solid Lipid Nanoparticle and Its Importance in Drug Delivery. International Journal of Drug Delivery Technology. 2024;14(1):531-536.

REFERENCES

  1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation, 2019.
  2. American Diabetes Standards of Medical Care in Diabetes—2021. Diabetes Care 2021; 44(Suppl. 1):S1–S232.
  3. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the Eur J Pharm Biopharm. 2000; 50(1):161-177.
  4. Wissing SA, Müller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin J Control Release. 2002; 81(3):225-233.
  5. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the Eur J Pharm Biopharm. 2000; 50(1):161-177.
  6. Almeida H, Amaral MH, Lobão P. Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs. Nanomaterials (Basel). 2020; 10(9):1773.
  7. Lakkireddy HR, Uppuluri KB, Chitrapu Solid lipid nanoparticles: A review on recent perspectives and patents. Expert Opin Ther Pat. 2012; 22(6): 10.1517/13543776.2012.685036.
  8. Patil-Gadhe A, Pokharkar Single-step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach. Int J Pharm. 2017; 526(1-2):35-51.
  9. Bansal S, Kashyap CP, Pal S, Sharma N, Gupta N, Yadav SLN approach for delivery of antidiabetic agent: A review. Int J Adv Pharm. 2018; 7(6):1-12.
  10. Patil-Gadhe A, Pokharkar Single-step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach. Int J Pharm. 2017;526(1-2):35-51.
  11. Jain S, Sapre R, Tiwary Role of solid lipid nanoparticles in drug delivery system. J Med Allied Sci. 2011; 1(2): 52-60.
  12. Kim JH, Kim YS, Park K, Kang E, Lee S, Nam HY, et al. Antitumor efficacy of cisplatin-loaded glycyrrhetinic acid- modified solid lipid nanoparticles on H22 tumor-bearing mice. Colloids Surf B Biointerfaces. 2014; 114: 100-105.
  13. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002; 41(9):661-680.
  14. Marathe PH, Wen Y, Norton J, Greene DS, Barbhaiya RH, Wilding Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 2000; 50(4):325-332.
  15. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998; 50(4):375-382.
  16. Shinde AJ, Patil SM, Deshmukh PK, Farooqui Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of felodipine. ISRN Pharm. 2013; 392658.
  17. Gupta H, Sharma A, Kumar S, Nandekar P. Recent trends in development of sustained release matrix tablets of antidiabetic drugs: A review. Int J Pharm Res Bio Sci. 2013; 2(3):12-26.
  18. Misra R, Acharya S, Dilnawaz F, Sahoo SK. Sustained antidiabetic effects of PEGylated liposomal formulation of insulin in streptozotocin-induced diabetic mice. Int J Nanomedicine. 2012; 7: 3991-4006.
  19. Jain A, Jain In vitro release kinetics model fitting of liposomes: an insight. Chem Phys Lipids. 2016; 201: 28-40.
  20. Riaz MK, Riaz MA, Zhang X, Lin C, Wong KH, Chen X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a Int J Mol Sci. 2018; 19(1):195.
  21. Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release. 2014; 190: 485-499.
  22. Patil-Gadhe A, Pokharkar Proliposomes: A novel approach to improve oral bioavailability of drugs. Indian J Pharm Sci. 2014; 76(5): 499-508.
  23. Narayan R, Nayak UY, Raichur AM, Garg Mesoporous silica nanoparticles: A comprehensive review on synthesis and recent advances. Pharmaceutics. 2018; 10(3):118.
  24. Alavi M, Karimi N, Safaei Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents. Drug Chem Toxicol. 2019; 42(2):144-151.
  25. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012; 430(1-2):216-227.
  26. Sharma N, Bansal M, Visht S, Sharma PK, Kulkarni GT. Solid lipid nanoparticles: a promising nanomaterial in drug delivery. Int J Pharm Sci Drug Res. 2010; 2(3):188-196.
  27. Soni G, Yadav KS. Applications of solid lipid nanoparticles in drug delivery systems. Current Research in Pharmaceutical Sciences. 2012; 2(2): 65-70.
  28. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and Nanoscale Res Lett. 2013; 8(1):102.
  29. Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol. 2015; 6: 219.
  30. Gaur PK, Mishra S, Purohit Enhancement of solubilization and bioavailability of poorly aqueous soluble and poorly permeable drugs through lipid nanoparticles. Int J Pharm Sci Rev Res. 2010; 1(2):1-9.
  31. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, et Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics. 2018; 10(4):191.
  32. Cun D, Foged C, Yang M, Frøkjær S, Nielsen HM. Preparation and characterization of insulin-loaded nanostructured lipid carriers for oral Eur J Pharm Sci. 2010; 41(3-4): 650-657.
  33. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery J Control Release. 2001; 70(1-2):1-20.
  34. Yu Y, Lau LC, Lo AH, Chau FT. Nanotechnological advances in transdermal delivery and therapy. Nanotechnol Rev. 2012; 1(2):241-258.
  35. Sánchez-López E, Espina M, Doktorovová S, Souto EB, García Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye – Part II – Ocular drug- loaded lipid nanoparticles. Eur J Pharm Biopharm. 2017; 110: 58-69.
  36. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the Eur J Pharm Biopharm. 2000; 50(1):161-177.
  37. Singh R, Lillard Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009; 86(3):215-223.
  38. Chidambaram M, Manavalan R, Kathiresan Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Sci. 2011; 14(1):67-77.
  39. Almeida AJ, Souto Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007; 59(6):478-490.
  40. Patil-Gadhe A, Pokharkar Single-step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach. Int J Pharm. 2017; 526(1-2):35-51.
  41. Wissing SA, Müller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin J Control Release. 2002; 81(3):225-233.
  42. Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Milani MA, Jelvehgari M. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery. Arch Pharm Res. 2021; 44(3):229-
  43. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012; 430(1-2):216-227.